Application No.: 10/077,555 Docket No.: HO-P02373US1

AMENDMENTS TO THE CLAIMS

1. (Original) A composition comprising an immune effector cell and a cell penetrating peptide, wherein said cell penetrating peptide is associated with an antigen.

- 2. (Original) The composition of claim 1, wherein the antigen is a tumor rejection antigen or tumor associated antigen.
- 3. (Original) The composition of claim 1, wherein the antigen is a molecule comprising multiple T-cell peptides.
- 4. (Original) The composition of claim 3, wherein the multiple T-cell peptides are from either the same tumor antigen or different tumor antigens.
- 5. (Original) The composition of claim 1, wherein the antigen comprises at least one MHC class I-restricted peptide, at least one MHC class II-restricted peptide, or at least one MHC class II-restricted peptide.
- 6. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell, a B cell, a macrophage, or a fibroblast.
- 7. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell or a B cell.
- 8. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell.
 - 9. (Original) The composition of claim 1, wherein the antigen is a tumor antigen.
 - 10. (Original) The composition of claim 9, wherein the tumor antigen is a peptide.
 - 11. (Original) The composition of claim 9, wherein the tumor antigen is TRP2.
- 12. (Original) The composition of claim 9, wherein the tumor antigen is one from Table 1, Table 2, Table 3, Table 4, or Table 5.

25564982.1

Application No.: 10/077,555 Docket No.: HO-P02373US1

13. (Original) The composition of claim 1, wherein the cell penetrating peptide is CPP1, ANTP, Signal-peptide I, Signal-peptide II, PRES, Transportan, Amphiphilic model peptide, HSV VP22, peptide carrier, or CL22.

- 14. (Original) The composition of claim 1, wherein the cell penetrating peptide is CPP1.
- 15. (Original) The composition of claim 1, wherein the association of the cell penetration peptide with the antigen is a covalent bond.
- 16. (Original) The composition of claim 1, wherein the antigen is housed within a vesicle in said immune system cell.
 - 17. (Original) The composition of claim 16, wherein the vesicle is an endosome.
 - 18. (Cancel)
 - 19. (Original) A vaccine comprising:

an immune effector cell and a cell penetrating peptide, wherein said cell penetrating peptide is associated with an antigen; and

a pharmaceutically acceptable carrier.

- 20. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell, a B cell, a macrophage, or a fibroblast.
- 21. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell or a B cell.
- 22. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell.

23.-46. (Cancel)

25564982.1